HIV‐1‐specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase
- 1 May 1993
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 13 (3), 229-258
- https://doi.org/10.1002/med.2610130303
Abstract
The TIBO, HEPT, nevirapine, pyridinone, BHAP, TSAO, and alpha-APA derivatives, although belonging to structurally diverging classes of molecules, share remarkable common features. They are specifically active against the reverse transcriptase of HIV-1 (TIBO and HEPT also, to a certain extent, against the reverse transcriptase of SIVagm strains), but not against the reverse transcriptases of HIV-2 or any other retroviruses. Nor are they active against any of the cellular DNA polymerases. These HIV-1-specific RT inhibitors seem to interact with a specific target site (YQYMDDLY) at positions 181-188, which is distinct from, but functionally and spatially related to, the substrate (dNTP) binding site. The tyrosine residues Y181 and Y188 play a crucial role in the interaction of TIBO and its congeners with their target site. The HIV-1-specific RT inhibitors have proven to inhibit the replication of various HIV-1 strains, including AZT-resistant HIV-1 strains, in different cell culture systems, including peripheral blood lymphocytes and monocyte/macrophages. In vitro they exhibit selectivity indexes of up to 5 orders of magnitude, which means that they are inhibitory to virus replication in cell culture at concentrations that are up to 100,000 times lower than the concentrations at which they are toxic to the host cells. As a rule, the HIV-1-specific RT inhibitors are orally bioavailable, as has been demonstrated with the TIBO and HEPT derivatives, nevirapine, pyridinones, and the alpha-APA derivatives in rats, dogs, monkeys, and humans. They sustain plasma drug levels that are well above the concentration required to inhibit virus replication in cell culture. Clinical studies have been undertaken with TIBO R82913, nevirapine, and pyridinones, and others (i.e., alpha-APA R89439) will soon follow. The problem of virus-drug resistance, which seems to readily emerge in vitro, will have to be addressed in the in vivo studies.Keywords
This publication has 47 references indexed in Scilit:
- Differential inhibitory effects of TIBO derivatives on different strains of simian immunodeficiency virusJournal of General Virology, 1992
- Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophagesAntiviral Research, 1992
- Activity of acyclic 6-(phenylselenenyl)pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytesJournal of Medicinal Chemistry, 1991
- A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templatesAntiviral Research, 1991
- NMR studies of an FK-506 analog [U-13C]ascomycin, bound to FKBP: conformation and regions of ascomycin involved in bindingJournal of Medicinal Chemistry, 1991
- Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine (HEPT) and recombinant alpha interferonAntiviral Research, 1991
- Specific anti-HIV-1 acyclonucleosides which cannot be phosphorylated: synthesis of some deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymineJournal of Medicinal Chemistry, 1991
- Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT)Journal of Medicinal Chemistry, 1991
- Molecular structure of a potent HIV-1 inhibitor belonging to the TIBO familyJournal of the American Chemical Society, 1991
- Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivativeBiochemical and Biophysical Research Communications, 1989